Ruby Birk

877 citations

14 papers · 349 indexed · h-index 6

Impact in

Pulmonary and Respiratory Medicine top 10%
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Respiratory Support and Mechanisms
- Inhalation and Respiratory Drug Delivery
- Respiratory and Cough-Related Research
Issues, ethics and legal aspects top 10%
- Nursing Diagnosis and Documentation

Papers in ⓘ

Physiology 12
- Asthma and respiratory diseases 12
Pulmonary and Respiratory Medicine 14
- Chronic Obstructive Pulmonary Disease (COPD) Research 13
- Inhalation and Respiratory Drug Delivery 9
- Respiratory Support and Mechanisms 4
- Respiratory and Cough-Related Research 3

Co-authors: David A. Lipson (12 shared papers)Noushin Brealey (12 shared papers)Chang‐Qing Zhu (11 shared papers)Maggie Tabberer (6 shared papers)David A. Lomas (4 shared papers)Nicholas Locantore (2 shared papers)Helen Barnacle (5 shared papers)Rajat Mohindra (1 shared paper)
Journals: Advances in Therapy (3 papers)ERJ Open Research (2 papers)Pediatric Pulmonology (1 paper)The Journal of Clinical Pharmacology (1 paper)Respiratory Research (1 paper)
Partner nations: United States United Kingdom Germany

In The Last Decade

Ruby Birk

13 papers receiving 345 citations

Peers

Countries citing papers authored by Ruby Birk

Since Specialization

Citations

This map shows the geographic impact of Ruby Birk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruby Birk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruby Birk more than expected).

Fields of papers citing papers by Ruby Birk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruby Birk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruby Birk. The network helps show where Ruby Birk may publish in the future.

Co-authors

The 25 scholars most cited alongside Ruby Birk, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ruby Birk Line = papers co-authored together Ruby Birk links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work
1	FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease American Journal of Respiratory and Critical Care Medicine ·David A. Lipson, Helen Barnacle, Ruby Birk, Noushin Brealey, Nicholas Locantore, David A. Lomas, Andrea Ludwig-Sengpiel, Rajat Mohindra, Maggie Tabberer, Chang‐Qing Zhu, Steven Pascoe	2017	226
2	Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study Respiratory Research ·Peter Bremner, Ruby Birk, Noushin Brealey, Afisi Ismaila, Chang‐Qing Zhu, David A. Lipson	2018	41
3	Once-Daily Triple Therapy in Patients with COPD: Patient-Reported Symptoms and Quality of Life Advances in Therapy ·Maggie Tabberer, David A. Lomas, Ruby Birk, Noushin Brealey, Chang‐Qing Zhu, Steve Pascoe, Nicholas Locantore, David A. Lipson	2018	21
4	Preventing clinically important deterioration with single-inhaler triple therapy in COPD ERJ Open Research ·Ian Naya, Chris Compton, Afisi Ismaila, Ruby Birk, Noushin Brealey, Maggie Tabberer, Chang‐Qing Zhu, David A. Lipson, Gerard J. Criner	2018	18
5	Once-Daily Triple Therapy in Patients with Advanced COPD: Healthcare Resource Utilization Data and Associated Costs from the FULFIL Trial Advances in Therapy ·Afisi Ismaila, Ruby Birk, Dhvani Shah, Shiyuan Zhang, Noushin Brealey, Nancy Risebrough, Maggie Tabberer, Chang‐Qing Zhu, David A. Lipson	2017	13
6	Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses ERJ Open Research ·David Halpin, Ruby Birk, Noushin Brealey, Gerard J. Criner, Mark T. Dransfield, Emma Hilton, David A. Lomas, Chang‐Qing Zhu, David A. Lipson	2018	13
7	Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease Clinical Pharmacokinetics ·Rashmi Mehta, Colm Farrell, Siobhán Hayes, Ruby Birk, Malek Okour, David A. Lipson	2019	4
8	Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium/Vilanterol via a Single Inhaler in Patients with COPD The Journal of Clinical Pharmacology ·Rashmi Mehta, Eleni Pefani, Misba Beerahee, Noushin Brealey, Helen Barnacle, Ruby Birk, Chang‐Qing Zhu, David A. Lipson	2018	3
9	Clinically important deterioration in advanced COPD patients using single inhaler triple therapy: results from the FULFIL study Ian Naya, Helen Barnacle, Ruby Birk, Noushin Brealey, Maggie Tabberer, Chang‐Qing Zhu, David A. Lipson	2017	3
10	A multicenter randomized, double‐blind, placebo‐controlled, parallel‐group study to evaluate the effects of a 1‐year regimen of orally inhaled fluticasone furoate 50 µg once daily on growth velocity in prepubertal, pediatric participants with well‐controlled asthma Pediatric Pulmonology ·Philippe Bareille, Varsha Imber, Jodie Crawford, Bernadetta Majorek‐Olechowska, Zeina Karam‐Absi, Sally Stone, Ruby Birk	2023	2
11	P272 Improvements in exacerbation rates with single inhaler triple therapy versus dual ics/laba therapy in patients with advanced chronic obstructive pulmonary disease (copd): subgroup analyses of the phase iii fulfil study HighWire Press Open Archive ·Emma Hilton, Noushin Brealey, Ruby Birk, CQ Zhu, G.J. Criner, M.T. Dransfield, David Halpin, DA Lomas, DA Lipson	2017	2
12	Single inhaler triple therapy in advanced COPD patients: prior medication and disease severity FULFIL subanalyses David A. Lipson, Helen Barnacle, Ruby Birk, Noushin Brealey, Chang‐Qing Zhu, Mark T. Dransfield, David A. Lomas	2017	2
13	LATE-BREAKING ABSTRACT: Single inhaler triple therapy (ICS/LAMA/LABA) in patients with advanced COPD: Results of the FULFIL trial David A. Lomas, David A. Lipson, Helen Barnacle, Ruby Birk, Noushin Brealey, Chang‐Qing Zhu, Maggie Tabberer	2016	1
14	24-Hour Serial Spirometric Assessment of Once-Daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-Daily Budesonide/Formoterol in Patients with COPD: Analysis of the FULFIL Study Advances in Therapy ·David A. Lipson, Ruby Birk, Noushin Brealey, Chang‐Qing Zhu	2020	0

About Ruby Birk

Ruby Birk is a scholar working on Physiology, Pulmonary and Respiratory Medicine, Infectious Diseases, Organic Chemistry and Surgery, having authored 14 papers that have together received 349 indexed citations. Recurring topics across this work include Chronic Obstructive Pulmonary Disease (COPD) Research (13 papers), Asthma and respiratory diseases (12 papers), Inhalation and Respiratory Drug Delivery (9 papers), Respiratory Support and Mechanisms (4 papers) and Respiratory and Cough-Related Research (3 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (339 citations), Issues, ethics and legal aspects (13 citations), Physiology (258 citations), Emergency Medical Services (13 citations) and Emergency Medicine (5 citations). Ruby Birk has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include David A. Lipson, Noushin Brealey, Chang‐Qing Zhu, Maggie Tabberer, David A. Lomas, Nicholas Locantore, Helen Barnacle, Rajat Mohindra, Andrea Ludwig-Sengpiel and Steven Pascoe. Their work appears in journals such as Advances in Therapy, ERJ Open Research, Pediatric Pulmonology, The Journal of Clinical Pharmacology and Respiratory Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact